Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FLT4 | P35916 | 13/20 | 0.49 |
| ▸ | JAK3 | P52333 | 3/20 | 0.45 |
| ▸ | JAK2 | O60674 | 1/20 | 0.45 |
| ▸ | PTK2 | Q05397 | 1/20 | 0.45 |
| ▸ | KDR | P35968 | 7/20 | 0.45 |
| ▸ | DDB1 | Q16531 | 1/20 | 0.45 |
| ▸ | CRBN | Q96SW2 | 1/20 | 0.45 |
| ▸ | IGF1R | P08069 | 1/20 | 0.42 |
| ▸ | EGFR | P00533 | 1/20 | 0.42 |
| ▸ | LCK | P06239 | 1/20 | 0.42 |
| ▸ | BTK | Q06187 | 1/20 | 0.42 |
| ▸ | TNK2 | Q07912 | 1/20 | 0.41 |
| ▸ | JAK1 | P23458 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15512982 | 0.92 | FLT4 (0.51) | FLT4JAK3JAK2KDRIGF1R | |
| SCHEMBL15513941 | 0.91 | FLT4 (0.52) | FLT4JAK3JAK2PTK2KDR | |
| SCHEMBL15524788 | 0.89 | JAK3 (0.47) | FLT4JAK3JAK2PTK2KDR | |
| SCHEMBL15512828 | 0.85 | FLT4 (0.49) | FLT4KDR | |
| SCHEMBL15524195 | 0.84 | JAK3 (0.47) | FLT4JAK3JAK2PTK2KDR | |
| SCHEMBL15513722 | 0.83 | FLT4 (0.51) | FLT4JAK3JAK2KDRIGF1R | |
| SCHEMBL15513700 | 0.82 | FLT4 (0.52) | FLT4KDRIGF1R | |
| SCHEMBL15523928 | 0.82 | FLT4 (0.43) | FLT4JAK3JAK2PTK2KDR | |
| SCHEMBL15524746 | 0.81 | FLT4 (0.53) | FLT4JAK3JAK2PTK2KDR | |
| SCHEMBL15512958 | 0.80 | FLT4 (0.51) | FLT4JAK3JAK2KDRIGF1R |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9238644-B2 | VEGFR3 inhibitors | CANCER THERAPEUTICS CRC PTY LIMITED (AU) | 2016-01-19 | — | — | US | disclosed |
| US-20160009686-A1 | VEGFR3 INHIBITORS | CANCER THERAPEUTICS CRC PTY LIMITED (AU) | 2016-01-14 | — | — | US | disclosed |
| US-20140073620-A1 | VEGFR3 INHIBITORS | CANCER THERAPEUTICS CRC PTY LIMITED (AU) | 2014-03-13 | — | — | US | disclosed |
| US-20080278069-A1 | Light Emitting Device | SEMICONDUCTOR ENERGY LABORATORY CO., LTD. | 2008-11-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160009686-A1 | VEGFR3 INHIBITORS | FLT4, FLT1, KDR | FLT4 1/4885JAK3 20/4885JAK2 82/4885 |
| US-20140073620-A1 | VEGFR3 INHIBITORS | FLT4, FLT1, KDR | FLT4 1/4885JAK3 20/4885JAK2 82/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.